Exicure (XCUR) announced the termination of its collaboration agreements with AbbVie (ABBV) and Ipsen BioPharm (IPSEY). Through separate agreements with AbbVie and Ipsen, Exicure was collaboratively advancing specified discovery programs in hair loss disorders and rare neurodegenerative disorders, respectively. As a result of this termination, Exicure regains the ability to independently develop medicines targeting hair loss disorders, Angelman syndrome, and Huntington’s disease – whilst Ipsen retains the right to re-enter into the collaboration with Exicure in Huntington’s Disease and Angelman’s Syndrome
Published first on TheFly
